56709-70-7

Basic information

• Product Name: ethyl 3-bromo-5-methoxybenzoate
• Synonyms: ethyl 3-bromo-5-methoxybenzoate;Methyl 5-bromo-m-anisate, 3-Bromo-5-(methoxycarbonyl)anisole;Benzoic acid,3-bromo-5-methoxy-, methyl ester
• CAS NO: 56709-70-7
• Molecular Formula: C₉H₉BrO₃
• Molecular Weight: 245.07
• Mol File: 56709-70-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 288℃
• Flash Point: 128℃
• Appearance: /
• Density: 1.462
• Refractive Index: 1.532
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ethyl 3-bromo-5-methoxybenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-bromo-5-methoxybenzoate(56709-70-7)
• EPA Substance Registry System: ethyl 3-bromo-5-methoxybenzoate(56709-70-7)

Safety Data

• Hazardous Substances Data: 56709-70-7(Hazardous Substances Data)

Usage

General Description

Ethyl 3-bromo-5-methoxybenzoate is a chemical compound that contains an ethyl group, a bromine atom, and a methoxy group attached to a benzene ring. It is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. ethyl 3-bromo-5-methoxybenzoate has important applications in the field of organic chemistry, where it can be used as a building block for the preparation of various complex molecules. It is also known for its potential biological activities and may have implications in medicinal chemistry. Additionally, it has been studied for its chemical reactivity and properties, making it a valuable tool for research and development in the scientific community.

InChI:InChI=1/C10H11BrO3/c1-3-14-10(12)7-4-8(11)6-9(5-7)13-2/h4-6H,3H2,1-2H3

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 74137-36-3 3,5-dibromoanisole 
• 618-58-6 3,5-dibromobenzoic acid 
• 140472-69-1 3-bromo-5-hydroxy-benzoic acid 
• 192810-12-1 3-bromo-5-hydroxy-benzoic acid methyl ester 
• 74-88-4 methyl iodide 
• 157893-14-6 3-bromo-5-methoxybenzoic acid 
• 762292-57-9 4-amino-3-bromo-5-methoxy-benzoic acid methyl ester 
• 186581-53-3 diazomethane 

Downstream Products

• 262450-64-6 (3-bromo-5-methoxyphenyl)methanol 
• 1186519-10-7 methyl 3-methoxy-5-(5-methylpyridin-2-yl)benzoate 
• 1427408-19-2 3-(3-fluorophenyl)-N-(3-hydroxy-2,6-dimethylphenyl)-5-methoxybenzamide 
• 1427408-20-5 3-[[3-(3-fluorophenyl)-5-methoxyphenyl]methylamino]-2,4-dimethylphenol 
• 1427408-21-6 C₂₇H₃₀FNO₄ 
• 1427408-22-7 C₂₆H₂₈FNO₄ 
• 1427406-54-9 C₂₃H₂₂FNO₄ 
• 1427406-55-0 C₂₄H₂₄FNO₄ 
• 1214369-81-9 5-methoxybiphenyl-3-carboxylic acid 
• 916343-77-6 3-cyclopropyl-5-methoxy-benzoic acid methyl ester 
• 889654-06-2 3-methoxy-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)benzoic acid methyl ester 
• 3889-89-2 mukoeic acid 
• 723-97-7 murrayanine 
• 4532-33-6 1-methoxy-3-methylcarbazole 

Relevant articles and documents

Total synthesis of carbazole alkaloids

A Suzuki-Miyaura cross coupling, followed by triphenylphosphine mediated Cadogan reductive cyclization sequence provided efficient access to a series of carbazole alkaloids. In the present work, this approach was applied to the total synthesis of mukonine, clauszoline K, koenoline, murrayanine, murrayafoline A, mukoeic acid, glycoborine, glycozolicine, mukolidine, mukoline, glycozoline, 3-methoxy-9H-carbazole-1-carboxylic acid methyl ester, (3-methoxy-9H-carbazol-1-yl)-methanol, 3-methoxy-9H-carbazole-1-carbaldehyde, 3-methoxy-9H-carbazole-1-carboxylic acid, 2-methyl-9H-carbazole and nonsteroidal anti-inflammatory drug (NSAID) carprofen and its derivatives.

DERIVATIVES OF 1 H-PYRAZOLO[3,4-B]PYRIDINE AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

The present invention discloses compounds according to Formula (I): wherein R1, R2, R3, R4, L, and X are as defined herein. The present invention relates to compounds,methods for their production, pharmaceutical

NOVEL PYRIMIDINE AND PYRIDINE COMPOUNDS AND USAGE THEREOF

Provided are novel pyrimidine and pyridine compounds of formula (I) or a pharmaceutical acceptable salt thereof, pharmaceutical compositions containing them, a process for preparing them, and their use in therapy of a disease responsive to inhibition of F